依折麦布治疗肝酶轻度异常高脂血症患者的疗效及安全性

Evaluation of the effectiveness and safety of ezetimibe on hyperlipidemia patients with liver enzyme mildly abnormal

目的观察依折麦布治疗肝酶轻度异常高脂血症患者的疗效及安全性。方法选择肝脏丙氨酸氨基转移酶轻度异常的高脂血症患者63例,随机分为2组。治疗组31例,给予依折麦布10mg,qd;多烯磷脂酰胆碱2片,tid,治疗共12周。对照组32例,给予阿托伐他汀20mg,qd;多烯磷脂酰胆碱2片,tid,治疗共12周。分别于入选时及治疗4、8、12周测定两组血脂、肝肾功能、血常规、血糖指标及观察2组不良反应发生情况。结果两组血脂水平均明显下降,治疗组用药前后肝肾功能、血常规无明显变化。结论依折麦布可作为肝酶轻度异常高脂血症患者的治疗选择,安全性良好。

A/M To evaluate the effectiveness and safety of ezetimibe on hyperlipidemia patients with liver enzyme mildly abnormal. METHODS Sixty-three patients were randomized into two groups：treatment group in which 31 patients were treated with ezetimibe and polyene phosphatidylcholine capsules , and control group in which 32 patients were treated with atorvastatin and polyene phesphatidylcholine capsules, with a course of 12 weeks. Before treatment, 2 weeks after treatment, 4 weeks after treatment, and 12 weeks after treatment, the adverse drug reactions and indexes including renal and liver function, blood lipids, complete blood count,and blood glucose were obseved. RESULTS Two groups have the effect in improving blood lipids, and there are no obvious changes of renal function and liver function and complete blood count for the treatment group. CONCLUSION Ezetimibe is an effective and safe medicine for hyperlipidemia patients with liver enzyme mildly abnormal.